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1  | INTRODUCTION
Primary functions of the mammalian brain are to perceive the 
features and details of the environment, give emotional value 
to the cues and contexts, and store or retrieve information that 
can be useful in new scenarios. As a result of these processes, 
motor or visceral responses can be performed following deter-
mined stereotypes using particular sets of forebrain intercon-
nections. These processes are, in turn, modulated by ascending, 
subcortical neural projections that enhance or reduce activities 
in different regions of the forebrain depending on the particu-
lar circumstances needed, levels of arousal, the time within the 
circadian rhythm or the level of metabolic demand. Cholinergic, 
dopaminergic, histaminergic, serotoninergic, adrenergic, and nor-
adrenergic projections to the forebrain have established roles in 
these modulatory actions.1-4 Indeed, agonists and antagonists, 
and allosteric or enzymatic modulators affecting these transmitter 
systems and their multiple receptors are the basis for the primary 
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Summary
The nucleus incertus (NI) in the pontine tegmentum sends ascending projections to 
the midbrain, hypothalamus, amygdala, basal forebrain, hippocampus, and prefrontal 
cortex, and has a postulated role in modulating several forebrain functions. A sub-
stantial population of GABAergic NI neurons expresses the neuropeptide, relaxin- 3, 
which acts via the Gi/o- protein- coupled receptor, RXFP3, present throughout the 
forebrain target regions. Broad and specific manipulations of these systems by acti-
vation or inhibition of the NI or modulating RXFP3 signaling have revealed key in-
sights into the likely influence of the NI/relaxin- 3/RXFP3 system on modalities 
including arousal, feeding, stress responses, anxiety and addiction, and attention and 
memory. This range of actions corresponds to a likely impact of NI/(relaxin- 3) projec-
tions on multiple integrated circuits, but makes it difficult to draw conclusions about 
a generalized function for this network. This review will focus on the key physiologi-
cal process of oscillatory theta rhythm and the neural circuits that promote it during 
behavioral activation, highlighting the ability of NI and relaxin- 3/RXFP3 signaling 
systems to modulate these circuits. A better understanding of these mechanisms 
may provide a way to therapeutically adjust malfunction of forebrain activity present 
in several pathological conditions.
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treatments of most neurological and mental illnesses.5 However, 
these systems are quite complex in nature, as these monoamine 
transmitters are coreleased with other transmitters including 
neuropeptides.6,7 Some of these transmitters may act via non-
synaptic mechanisms, such as extra- synaptic receptors or volume 
transmission.8,9 Notably, some long, ascending projections from 
the brainstem use GABA as a primary (fast) transmitter, which is 
coexpressed with a number of different transmitters/modulators. 
One such GABA network arises from the nucleus incertus (NI) in 
the pontine tegmentum and these large GABA neurons coexpress 
neuropeptides including relaxin- 3, cholecystokinin, and neurome-
din- B10 (Figure 1A- D). Unlike the monoamine transmitter systems 
that have been extensively characterized experimentally, the NI 
GABA/peptide system is still relatively uncharacterized. This re-
view is focused on basic mechanisms at the cellular level (eg, ERK 
phosphorylation) and the system level (eg, theta rhythm) that are 
controlled by the NI GABA/relaxin- 3 system, and that may be 
common to most functions modulated by this system.
2  | NUCLEUS­INCERTUS
The term nucleus incertus (Latin for “uncertain nucleus”) was first in-
troduced by George Streeter11 to describe a group of neurons in the 
human brain located in the midline of the floor of the 4th ventricle at 
the level of the genu of the facial nerve. Thereafter, in 2001, a pre-
cise anatomical study12 revealed a widespread neural network origi-
nating in the NI that was distributed throughout various midbrain 
and forebrain areas. This NI network was subsequently confirmed 
and its description extended.13
Originally, it was proposed that the NI system functions via a 
strong triangular circuit involving the NI, median raphe and inter-
peduncular nuclei, with ascending connections from these nodes 
producing a general activation of forebrain circuits including the 
hippocampus (Figure 2A).11 We further proposed that the NI is 
engaged in bidirectional communication between the septohip-
pocampal system and the NI, as analysis revealed that the NI suc-
cessively connects regions that, in turn, project to the next node, 
so that the hippocampus receives the cumulative connections of 
all nuclei/areas within the pathway. Successive connections in 
this major pathway involve the median raphe, interpeduncular 
nucleus, supramammillary nucleus, medial septum, and the hip-
pocampus (Figure 2B).12 We have additionally observed that the 
medial septum is a source of descending projections to the NI.13
These early studies were motivated by the observation that 
NI neurons in the rat brain express a high level of corticotropin- 
releasing factor receptor- 1 (CRF1) mRNA,
14,15 which suggested the 
NI may mediate behavioral responses to stressful conditions.
F IGURE  1 Morphological features of the rat nucleus incertus (NI). A, A Giemsa- stained section of the pontine tegmentum at the 
level of the floor of the 4th ventricle (IV). The NI (outlined) is composed of the pars compacta in the midline (NIc) and the pars dissipata 
(NId), just dorsal to the medial longitudinal fasciculus (mlf), with the posterodorsal tegmentum (PDTg) and the sphenoid nucleus (Sph) 
dorsolateral to the NI at this level. B, An injection site (is) for the retrograde tracer, fluorogold (FG) in the dentate gyrus of the caudo- ventral 
hippocampus, displaying some retrograde labeling in the entorhinal cortex (Ent). C, Retrograde labeling in the ipsilateral NI resulting from 
the injection in (B), with some retrograde labeling in the contralateral NI. D, Immunohistochemical detection of relaxin- 3 (RLN3) in the NI. E, 








Concurrent with the mapping of NI anatomical connections, the 
neuropeptide, relaxin- 3, was identified in human, mouse, and rat and 
its expression in different tissues was reported.16,17 Using in situ hy-
bridization and immunohistochemistry, the peptide was found to be 
highly expressed in an area in the ventromedial pontine tegmentum 
that corresponded to the NI.10,17,18 In addition to the large NI popula-
tion, smaller populations of relaxin- 3 neurons were observed in the 
central periaqueductal gray, lateral part of the substantia nigra, and 
pontine raphe nucleus.10,18-20 In NI neurons, relaxin- 3 is coexpressed 
with the major inhibitory transmitter, GABA, and the distribution 
pattern of relaxin- 3 fibers is similar among rodents and in primate 
brain.10,18,19 Similar anatomical characteristics of the NI, relaxin- 3 
neurons, and their projections in the Macaca fascicularis have also 
been described.20
Analysis of different taxa revealed relaxin- 3 as the ancestral form 
of the relaxin family peptides in vertebrates.21 The native peptide is 
synthetized from the preprorelaxin- 3 gene, and mRNA is translated 
to a peptide which is cleaved into 3 peptides (A, B and C), with pep-
tides A and B linked by 2 disulfide bonds. The B- peptide contains the 
characteristic sequence “RXXXRXX(I/V)” which is key to the inter-
action with the peptide’s receptor.16 Phylogenetic evidence revealed 
that the relaxin- 3 gene emerged before the divergence tree of verte-
brates and the ancestral form of the relaxin family is a relaxin- 3- like 
peptide. In zebrafish, mRNA expression is diffuse in early develop-
ment until 72 days postpharyngula stage and then abundant tran-
scripts appear in the periaqueductal gray and the brainstem, in a 
structure identified as the NI equivalent in Danio nerio.22
Shortly after the discovery of relaxin- 3, a type 1 G- protein- 
coupled receptor, GPCR135 (renamed “RXFP3”),23 was identified as 
its cognate receptor. Relaxin- 3 binds to RXFP3 with high affinity (Kd 
300 pmol/L) and RXFP3 activation produces inhibition of cAMP, nor-
mally associated with Gi/o- protein coupling.
24,25 Studies in Chinese 
hamster ovary (CHO- K1) cells transfected with RXFP3 revealed that 
receptor activation also resulted in ERK1/2 phosphorylation.26
Chemical modifications of the relaxin- 3 structure have produced 
specific RXFP3 agonists and antagonists,27-29 which have provided 
several functional insights into relaxin- 3/RXFP3 biology. Further 
insights have also been obtained by studying the phenotype of 
F IGURE  2 Two schematic models of NI connectivity. A, Based on their anatomical mapping studies, Goto et al11 proposed a strong 
neural circuit between the median raphe (MR), the interpeduncular nucleus (IPN) and the NI and proposed that from this circuit, ascending 
projections could reach the ventral tegmental area (VTA), supramammillary nucleus (SuM), hypothalamus (Hyp), medial septum (MS), 
hippocampus (Hip), and the medial prefrontal cortex (mPFC). B, In subsequent studies, Olucha- Bordonau et al12 proposed a series of 
overlapping ascending projections from the NI to the hippocampus, in which each progressive step recapitulated previous projections on 
route to the hippocampus. This scheme also incorporated the bed nucleus of the stria terminalis (ST) and the amygdala (Amy). Descending 
projections from the septum, hypothalamus, and lateral habenula (LHb) are also illustrated, which constitute a bidirectional pathway13
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mice lacking the relaxin- 3 or RXFP3 gene and peptide/protein.30-32 
Studies employing direct activation or inactivation of the NI and its 
neuronal inputs and targets have also provided information about 
the likely roles of relaxin- 3/RXFP3 systems. Thus, considerable data 
implicates the relaxin- 3/RXFP3 system in arousal and motivated 
feeding and drug- seeking behavior, stress responses and anxiety, 
and attention and memory.33-35 Several investigations have ex-
amined the neurophysiological events that are driven by the NI/
relaxin- 3 networks, with consistent effects observed on the sep-
tohippocampal system and hippocampal theta rhythm, and on ex-
pression of immediate early genes and transcription factors in target 
nuclei,36,37 but further studies are required of these processes that 




The pattern of forebrain connections of the NI was consistent with 
the ascending brainstem control of the hippocampus either directly 
or through the septal area,12,38 and this observation led to a series of 
experiments that confirmed the role of the NI/relaxin- 3/RXFP3 sys-
tem in control of hippocampal theta rhythm. Stimulation of the NI in 
urethane- anesthetized rats induced hippocampal theta and lesion of 
the NI eliminated the hippocampal theta activity produced by elec-
trical stimulation of the nucleus reticularis pontis oralis (RPO).39 Similar 
effects were observed after manipulations of the relaxin- 3/RXFP3 
system. Notably, injection of an RXFP3 agonist into the medial sep-
tum induced hippocampal theta rhythm and affected exploration 
and spatial working memory in the spontaneous alternation test.40 
Septal infusion of an RXFP3 antagonist impaired RPO stimulation- 
induced theta.40 Furthermore, there was a correlation between the 
phase of theta oscillations in the hippocampus and in NI,36 and there 
is a causal interdependence between hippocampal theta rhythm and 
NI firing, whereby different types of neurons drive the flow of the 
causality either from the NI to the hippocampus or vice versa.41,42
Nucleus incertus neurons express high levels of CRF1 mRNA,
15 
suggesting a role for the nucleus in relaying stress response signals 
to telencephalic circuits. In a recent study, we determined that the 
NI is composed of different populations of neurons, but all RLN3 
neurons express CRF1 and intracerebroventricular (icv) infusion of 
CRF- activated relaxin- 3 neurons.36 Furthermore, a recent study re-
ported that CRF infusion into the NI impaired long- term potentiation 
in the medial prefrontal cortex produced by hippocampal stimula-
tion,43 suggesting the hippocampus- prefrontal cortex (and amyg-
dala) circuit is modulated by relaxin- 3- containing GABA afferents.
A major target of NI projections is the medial septum,38 which in 
turn sends projections to the hippocampus and amygdala and to a 
lesser extent the cerebral cortex. The pathways arising from the NI 
and extending across the telencephalic “emotional” centers appear, 
for the most part, to parallel the monoaminergic systems. These data 
lead us to consider the ascending NI- relaxin- 3/RXFP3 system as an 
important arousal network that represents a putative target of the 
pathology associated with mental illnesses and/or a therapeutic tar-
get for drug development.33,44,45
There has been less research on the consequences of intrinsic 
neuronal mechanisms driven by RXFP3 activation. Ex vivo studies 
reported that RXFP3 activation induced ERK phosphorylation and 
inhibition of cAMP synthesis.24,26 In vivo studies observed neuro-
nal ERK phosphorylation in the septum following icv injection of an 
RXFP3 agonist,37 but more recent studies suggest this effect within 
cholinergic neurons was indirect via RXFP3 activation of presyn-
aptic circuits or local GABA interneurons.46 Patch- clamp studies in 
the intergeniculate thalamic nucleus and the paraventricular hypo-
thalamic nucleus indicated that the primary direct effect of RXFP3 




Manipulating the relaxin- 3/RXFP3 system consistently alters feeding 
behavior in rats. Direct hypothalamic or icv infusion of relaxin- 3 re-
sulted in an increase in cumulative food intake in satiated rats 1- 4 hours 
postinjection.49 Similar effects were observed when RXFP3- specific 
agonists were administered, which were attenuated by prior infu-
sion of an RXFP3 antagonist.50 The NI is activated by stressors that 
may alter energy balance and food intake,51,52 and sex differences 
in relaxin- 3/RXFP3 signaling related to feeding behavior have been 
described.52 Chronic stress and repeated food restriction increased 
body weight gain in female, but not male Wistar rats, which was asso-
ciated with significantly increased relaxin- 3 mRNA levels in the NI of 
female, but not male rats, compared to controls.52 The gender- specific 
effect of relaxin- 3 is further highlighted by the fact that this neuro-
peptide has been shown to produce a significant increase in plasma 
corticosterone and the expression of CRF and c- fos mRNAs in the 
parvocellular paraventricular hypothalamic nucleus (PVN) in male, but 
not female rats. Subsequently, female rats displayed greater sensitiv-
ity and a stronger food intake increase in response to relaxin- 3 treat-
ment.53 In a model of stress- induced binge eating, female rats were 
prone to develop binge- like eating and displayed increased relaxin- 3 
mRNA in the NI compared to binge eating- resistant rats.54
Modulation of relaxin- 3/RXFP3 signaling also alters feeding be-
havior in mice, under some conditions.34 It has also been observed 
in mice that icv injection of RXFP3 antagonists affects behaviors re-
lated to food intake. These effects include reduced food anticipatory 
activity before meal time during food restriction, consumption of 
highly palatable food, consumption of regular chow during the initial 
dark phase, and consumption of regular chow after mild food depri-
vation.55 Specific effects on salt appetite have also been reported in 
mice, whereby icv injection of an RXFP3 antagonist reduced the vol-
ume of salt consumed in a dose- dependent manner, when offered to 
sodium- depleted mice, relative to vehicle- treated controls; and this 
effect was not observed in Rxfp3 gene knockout mice.56
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5.2 | Stress­and­anxiety
The putative role of the relaxin- 3/RXFP3 system in stress and anxi-
ety behavior was first highlighted by the strong expression of CRF1 
mRNA in the rat NI.14,15 It was subsequently observed that icv CRF 
infusion activated relaxin- 3 positive neurons in the rat NI18 and 
stressful stimuli- modified relaxin- 3 expression in the NI.57 Repeated 
forced swim stress increased relaxin- 3 heteronuclear and mRNA lev-
els, 1- 2 hours after the second swim, and these effects were attenu-
ated by prior injection of the CRF1 antagonist, antalarmin.
57
Central (icv) injection of RXFP3 agonist was found to induce an 
anxiolytic effect in the elevated plus maze and light/dark box tests 
in rats.58 However, the anxiolytic effect of RXFP3 activation appears 
to depend on the basal emotional condition prior to testing. In non-
stressed, naive mice, icv infusion of RXFP3 agonist did not alter anx-
iety levels, which was significantly reduced after treatment with an 
anxiogenic benzodiazepine,59 suggesting that endogenous relaxin- 3/
RXFP3 signaling may not strongly participate in regulating basal levels 
of anxiety. In this regard, one strain of relaxin- 3 gene knockout mice 
was reported to display mild anxiety- like behavior, although the phe-
notype was not consistently observed.60 In another strain, Rxfp3 gene 
knockout mice displayed reduced activity in the voluntary home- cage 
running wheels and decreased anxiety- like traits in the elevated plus 
maze.31 The NI has also been proposed to contribute to the anxiogenic 
effects of high doses of buspirone, a clinically used anxiolytic drug,61 
as an anxiogenic effect was observed after direct injection of bus-
pirone into the NI and this effect was abolished by prior NI lesion.61
5.3 | Alcohol-­seeking
Relapse represents one of the most difficult clinical problems in 
treating patients with alcohol- use disorders. In a rat model of alco-
hol use and alcohol- seeking, icv administration of RXFP3 antagonist 
has been shown to decrease self- administration of alcohol in a dose- 
related manner, and attenuate cue- and stress- induced reinstatement 
following extinction.62 No effect of the antagonist injections was ob-
served on sucrose- seeking or general food intake behavior, indicat-
ing specific regulation of alcohol intake and relapse- like behavior.62 
Furthermore, there was a positive correlation between relaxin- 3 
mRNA levels in the NI and levels of alcohol intake in alcohol- preferring 
rats.63 Addiction and relapse are strongly driven by stress and anxi-
ety, and injection of a relaxin- 3 antagonist into the central amygdala 
has been reported to attenuate the relapse to alcohol induced by the 
anxiogenic drug, yohimbine.64 Reinstatement of alcohol- seeking was 
also disrupted by intra- NI infusion of a CRF1, but not CRF2, receptor 
antagonist.65 Similarly, bilateral NI infusion of an orexin- 2 (OX2), but 
not OX1, receptor antagonist decreased reinstatement of alcohol- 
seeking,66 which is consistent with the presence of an orexin innerva-
tion of OX2- positive neurons in the rat NI.67
The mesolimbic system, which is a pivotal element in neural re-
ward mechanisms, is not strongly or directly linked to NI circuits, but 
other regions, such as the hippocampus and the amygdala, are capa-
ble of modulating components of the mesolimbic system involved in 
reward and addictive processes. For example, mice receiving chronic 
morphine treatment display a strong increase in CA1 theta rhythm.68 
Moreover, theta burst stimulation of the hippocampal ventral subic-
ulum, which projects to the nucleus accumbens, resulted in a blunted 
reinstatement of cocaine consumption.69 It has also been found that 
intermittent alcohol self- administration is sufficient to reduce theta 
synchrony in the hippocampus, amygdala and prefrontal cortex.70 
Thus, it is likely that signaling pathways downstream of RXFP3 ac-
tivation are involved in alcohol- seeking and relapse, and synchro-
nization in the theta band, a process driven by the NI- relaxin- 3 
projection to the septum and hippocampus.
5.4 | Arousal
Strong anatomical data suggest the NI and the associated relaxin- 3/
RXFP3 system could be involved in adapting cognitive and emotional 
functions to circadian activity. The NI strongly projects to the median 
preoptic and ventrolateral preoptic nuclei, lateral hypothalamic area, 
medial division of the lateral habenula, dorsal raphe, and interpeduncu-
lar nuclei.11,12 All these nuclei have been associated with shifts between 
different sleep states including wake, slow wave sleep (SWS), and rapid 
eye movement (REM) sleep.71-73 In addition, NI neurons express recep-
tors for transmitters/neuropeptides involved in these processes, includ-
ing orexin receptors OX1 and OX267,74,75 and melanin- concentrating 
hormone (MCH) receptors.76 In this regard, the firing of NI neurons 
can be activated by orexin- A77 and inhibited by MCH (Blasiak A, Ma S, 
Gundlach AL, unpublished data). However, there is currently no direct 
indication of the role of NI relaxin- 3/RXFP3 signaling in shifting sleep/
wake states and circadian rhythmicity.77 Nonetheless, icv infusion of 
the Rxfp3 agonist, R3/I5, increased arousal- related locomotor activity 
and exploration, and increased wakefulness;78 and relaxin- 3 and Rxfp3 
gene knockout mice display circadian hypoactivity manifested by re-
duced running wheel activity and increased inactivity and sleep dura-
tion during the dark, active phase.30,31
All these data are consistent with a role for the NI and relaxin- 3/
RXFP3 systems in promoting active behavior. Notably, ipsilateral mi-
crostimulation of the NI in rats produced increased locomotion and 
rotation behavior,79 and icv infusion of a relaxin- 3 agonist produced 
increased locomotor activity of rats in a T- maze, although this was 
accompanied by a disruption in natural spontaneous alternation.37 
In recent studies, sustained chemogenetic activation of NI neurons 
in rats produced long- lasting locomotor activity, associated with in-
creased vigilance behavior (head- scanning) following fear condition-
ing, effects paralleled by increased cortical electroencephalograph 
(EEG) desynchronization, and increased theta rhythm activity.80
5.5 | Learning­and­memory
Given the direct connections of NI- relaxin- 3 neurons with struc-
tures directly involved in memory processes, the effects of in-
terference with RXFP3 signaling on spatial memory have been 
investigated. Infusion of RXFP3 antagonist into the septal area re-
sulted in disruption of spatial working memory in the spontaneous 
     |  699OLUCHA- BORDONAU et AL.
alternation test,40 while icv infusion of an agonist induced impair-
ment of short- term memory in the T- maze.37 While these results 
seem contradictory, these paradigms measure different aspects of 
memory (spatial working memory and short- term spatial memory), 
and the mode of RXFP3 modulation was different in each test.
The effects of interference with NI activity on spatial memory 
has also been analyzed using transient lidocaine inactivation of 
NI neurons,81,82 which impaired long- term spatial memory in the 
Morris water maze81 and impaired retention in a passive avoid-
ance learning task.82 In the latter study, it was proposed that the 
increased excitability promoted by the NI may facilitate process-
ing along the trisynaptic pathway. Using a direct approach, Cre- 
dependent deletion of RXFP3 in receptor- positive hilar neurons of 
the dentate gyrus in mice, impaired spatial alternation assessed in 
a Y- maze.83
Furthermore, oscillatory hippocampal theta activity can be 
driven by a specific type of parvalbumin- positive, GABAergic sep-
tal neuron, named as Teevra cells, which selectively innervate CA3 
interneurons and pyramidal cell assemblies, to modulate phase- 
firing during hippocampal theta activity.84 The fact that RXFP3 is 
broadly expressed in septal GABAergic neurons,46 some of which 
are likely to be parvalbumin- positive, further highlights the likely 
role of relaxin- 3 transmission in driving hippocampal theta rhythm. 
In addition, optogenetic induction of hippocampal theta oscillations 
by rhythmic activation of glutamatergic septal neurons is associ-
ated with initiation of locomotion within hundreds of milliseconds 
of stimulus onset.85 The association of theta rhythm activation and 
locomotor induction may underlie the well- characterized effects 
of NI and relaxin- 3 neuron activity in promoting movement.37,79,80
5.6 | Affective­behavior
The amygdala receives relaxin- 3- positive projections from the 
NI.12,86 The medial amygdala nuclei and medial nuclei of the bed nu-
cleus of the stria terminalis are among the areas containing the dens-
est NI neuron and relaxin- 3 fibers, although fibers are also dispersed 
F IGURE  3 Organization of the connections of the NI and its specific targets. A loop in the brainstem exists where the median raphe 
induces theta desynchronization, and the reticularis pontis oralis (RPO) is the source for tonic firing during somatosensory stimulation and 
may relay on the NI. The NI can integrate stress- related information to activate arousal, emotion, and learning and memory mechanisms 
in a set of ascending connections. At the next level, the supramammillary nucleus (SuM) modulates NI firing to regulate rhythmic output 
to the septum, which is a primary regulator of rhythmic input to the hippocampus. Several neural circuit loops can be anatomically 
defined. (1) The central processing loop is composed of the lateral habenula (LHb), the interpeduncular nuclei (IPN) and the NI. (2) The NI 
also receives hypothalamic projections from corticotropin- releasing factor (CRF) and orexin (Orx) peptidergic projections and also from 
GABAergic projections arising from the septal area. (3) The NI receives projections from the RPO which is responsible for driving theta from 
somatosensory stimulation. (4) The NI then sends ascending connections to the median raphe (MR), supramammillary nucleus (SuM), medial 
septum/diagonal band (MS/DB), and hippocampus, which largely underlie subcortically- driven theta rhythm. (5) NI projections also innervate 
the extended amygdala, which is important for emotionally- driven behaviors, including addictive behaviors and anxiety. (6) Some of these 
behaviors, such as feeding, could be modulated by NI projections to hypothalamic nuclei and interactions with other peptidergic systems 
(Pep)
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in other amygdaloid nuclei, in close contact with some calcium- 
binding protein- positive neurons.86 These data suggest a role of the 
system in affective (emotion)- related behaviors. Selective lesion of 
the NI with saporin- CRF has been found to prolong freezing in a fear 
conditioning paradigm87 and electrolytic lesions of NI impair normal 
extinction88 in rats. In contrast, as mentioned, excitatory DREADD 
activation of the NI in rats resulted in increased head- scanning and 
vigilant behaviors during conditioned fear recall.80
6 | A­UNIFIED­ROLE­FOR­THE­NI-­RELAXIN-­3/ 
RXFP3­SYSTEM?
As discussed, existing data suggest the NI neural network and 
its relaxin- 3/RXFP3 signaling component alter a wide variety of 
somewhat independent behaviors. A major driver of NI function 
in the rat is CRF/CRF1 signaling, which presumably arises from 
the hypothalamus36 and potentially from local CRF neurons,89 in 
addition to orexin inputs activating OX2 receptors in the NI.66,67 
Therefore, under stressful conditions, a widespread neural reac-
tion can be driven from a broad network of GABA/peptidergic 
connections involving the brainstem, hypothalamus, amygdala, 
septum, hippocampus, and prefrontal cortex. At the molecu-
lar level, the consequences of RXFP3 activation are inhibition 
of cAMP synthesis and possibly phosphorylation of ERK. At the 
behavioral level, activation of the NI promotes locomotor activ-
ity.37,79,80 Another consequence of NI activation is the occurrence 
of theta oscillations in the hippocampus39,40 (Figure 3). These syn-
chronized oscillations may be maintained by bidirectional connec-
tions between the hippocampus and the NI,13 which provide phase 
locking between the brainstem and hippocampal circuits.36,41 
Theta synchronization also occurs between the prefrontal cortex, 
hippocampus, and amygdala, during fear acquisition and retrieval 
processes.90 Thus, the NI and relaxin- 3/RXFP3 signaling may work 
to induce intracellular metabolic cascades in their target areas, in-
cluding cAMP inhibition and ERK phosphorylation, which enable 
mutual and somehow reciprocal neural interconnections, resulting 
in oscillatory synchrony in several areas such as the hippocam-
pus. As a result, arousal mechanisms are potentiated and memory 
processes are modulated, which subserve a variety of functions, 
including spatial learning, anxiety processes, feeding behavior, and 
alcohol- seeking. Further knowledge of how this system modulates 
these processes may offer a new therapeutic perspective on treat-
ing malfunctions associated with neuropathology and psychiatric 
disorders.
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